From what 0 stock analysts predict, the share price for ImmunoGen Inc (IMGN) might decrease by 100% in the next year. This is based on a 12-month average estimation for IMGN. Price targets go from $ to $. The majority of stock analysts believe IMGN is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
ImmunoGen Inc has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that ImmunoGen Inc will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of IMGN.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Data Not Found! |
When did it IPO
1989
Staff Count
277
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Mark Joseph Enyedy
Market Cap
$8.72B
In 2023, IMGN generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that IMGN's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
No news data available.